Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 3, 2026

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

Conference Report: update on screening methodologies.

Ana Isabel Bardera1, Julio Martin

  • 1GlaxoSmithKline, Centro de Investigación Básica S.L., Santiago de Grisolia, 4, 28760 Tres Cantos, Madrid, Spain.

Future Medicinal Chemistry
|March 24, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of novel bromodomain inhibitors of <i>Trypanosoma cruzi</i> bromodomain factor 2 (<i>Tc</i>BDF2) using a fluorescence polarization-based high-throughput assay.

Antimicrobial agents and chemotherapy·2024
Same author

Structure-Guided Design and Synthesis of a Pyridazinone Series of <i>Trypanosoma cruzi</i> Proteasome Inhibitors.

Journal of medicinal chemistry·2023
Same author

Longitudinal findings of a U.S. preventive evidence-based family intervention tested among youth in Ecuador: Familias Unidas.

PLOS global public health·2023
Same author

Bromodomain factor 5 is an essential regulator of transcription in Leishmania.

Nature communications·2022
Same author

Essential Bromodomain <i>Tc</i>BDF2 as a Drug Target against Chagas Disease.

ACS infectious diseases·2022
Same author

Genomic and Phenotypic Characterization of Experimentally Selected Resistant Leishmania donovani Reveals a Role for Dynamin-1-Like Protein in the Mechanism of Resistance to a Novel Antileishmanial Compound.

mBio·2022
Same journal

Indole-based carbohydrazides as potent anti-proliferative leads and tubulin polymerization inhibitors: design, synthesis, cytotoxic evaluation, <i>in silico</i> ADMET and docking studies.

Future medicinal chemistry·2026
Same journal

Recent advances in the development of small molecule STK33 inhibitors.

Future medicinal chemistry·2026
Same journal

Biological evaluation and molecular docking of previously reported pyrazolo-thiazole derivatives as dual α-amylase and α-glucosidase inhibitors.

Future medicinal chemistry·2026
Same journal

Coumarin derivatives as antidiabetic agents: a comprehensive review on mechanistic insights, structure-activity relationships, <i>in silico</i> studies, and challenges.

Future medicinal chemistry·2026
Same journal

Expanding the tetrazole space: medicinal chemistry, biological diversity and structure-activity relationships.

Future medicinal chemistry·2026
Same journal

Thiazolidin-based dual Aurora kinase inhibitors with potent anticancer activity.

Future medicinal chemistry·2026
See all related articles

Screening Europe 2009 showcased advancements in high-throughput screening (HTS) and high-content screening (HCS) techniques for drug discovery. The conference highlighted key drug targets, including kinases, G-protein-coupled receptors (GPCRs), and ion channels, fostering academic and industry collaboration.

Area of Science:

  • Biotechnology and Pharmaceutical Sciences
  • Drug Discovery and Development
  • Molecular Biology and Pharmacology

Background:

  • The 2009 Screening Europe conference, co-located with MedChem and ADMET Europe, convened 350 delegates from academia and industry.
  • The event focused on contemporary assay techniques crucial for modern drug discovery pipelines.

Framework:

  • The scientific program was structured into two concurrent themes: screening methods and drug targets.
  • Sessions covered high-content screening (HCS), cell-based assays, advances in screening techniques, and label-free screening.
  • Drug target sessions concentrated on ion channels, protein kinases, and G-protein-coupled receptors (GPCRs).

Implementation:

  • Case studies presented promising drug discovery candidates and their development pathways.

More Related Videos

Universal Screening for Prevention of Reading, Writing, and Math Disabilities in Spanish
14:43

Universal Screening for Prevention of Reading, Writing, and Math Disabilities in Spanish

Published on: July 18, 2020

Related Experiment Videos

Last Updated: Jun 3, 2026

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score (PRIUS): A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

Universal Screening for Prevention of Reading, Writing, and Math Disabilities in Spanish
14:43

Universal Screening for Prevention of Reading, Writing, and Math Disabilities in Spanish

Published on: July 18, 2020

  • Discussions emphasized the practical application of high-throughput screening (HTS) and HCS in identifying novel therapeutics.
  • The integration of diverse screening methodologies was explored to enhance efficiency and success rates in drug development.

    • Implications:

    • The conference facilitated knowledge exchange on cutting-edge screening technologies and target identification strategies.
    • It underscored the importance of interdisciplinary collaboration in accelerating the drug discovery process.
    • Insights gained are vital for optimizing assay development and advancing therapeutic interventions for various diseases.